-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Eosinophilia includes a wide range of non-hematological (secondary or reactive) and hematological (primary or clonal) diseases, and may lead to end-organ damage
.
An article published in AMERICAN JOURNAL OF HEMATOLOGY recently updated the diagnosis, risk stratification and management of eosinophilic diseases
Diagnosis :
Diagnosis : Diagnosis :Diagnosis:DiagnosisHypereosinophilia is usually defined as a peripheral blood eosinophil count greater than 1.
5×10 9 /L, which may be related to tissue damage
.
After excluding secondary causes of eosinophilia, the diagnostic evaluation of primary eosinophilia relies on a combination of various tests, including morphological review of blood and bone marrow, standard cytogenetics, Fluorescence in situ hybridization and flow immunophenotyping to detect histopathological or clonal evidence of non-acute or chronic hemolymphoid tumors
immunity
Risk stratification:
Risk stratification: Risk stratification: Risk stratification:The prognosis of the disease depends on identifying the subtype of eosinophilia
.
After evaluating the secondary causes of eosinophilia, the World Health Organization approved a semi-molecular classification scheme for disease subtypes in 2016
Risk adaptation treatment:
Risk adaptation treatment: Risk adaptation treatment:The purpose of treatment is to reduce organ damage mediated by eosinophils
.
Patients with mild eosinophilia (such as <1.
Manage stem cells
Original source:
Shomali, W.
Shomali, W.
and Gotlib, J.
(2021), World Health Organization-defined eosinophilic disorders: 2021 update on diagnosis, risk stratification, and management.
Am J Hematol.
Accepted Author Manuscript.
https://doi.
org/10.
1002/ ajh.
26352 Leave a message here
